Literature DB >> 14741327

The 3' region of the DRD2 gene is involved in genetic susceptibility to schizophrenia.

Caroline Dubertret1, Laurent Gouya, Naima Hanoun, Jean-Charles Deybach, Jean Adès, Michel Hamon, Philip Gorwood.   

Abstract

The gene coding for the D2 dopamine receptor (DRD2) is considered as one of the most relevant candidate genes in schizophrenia. Previous genetic studies focusing on this gene yielded conflicting results, for example because of differences in methodology (linkage versus association studies) and variability in the loci analyzed (the DRD2 gene having many polymorphic sites). We used a progressive strategy with two different approaches (case-control and transmission disequilibrium test) and investigated six genetic polymorphisms spanning the DRD2 gene in 103 patients with DSM-IV criteria of schizophrenia, their 206 parents and 83 matched healthy control subjects. We found a significant excess of the A2 allele in subject with schizophrenia compared to unaffected controls. An excess of transmission of the A2 allele (and haplotypes containing this marker) from the parents to the affected children was also observed. Interestingly, the TaqI A1/A2 polymorphism, located 9.5 kb downstream from the DRD2 gene, maps in a novel gene, untitled "X-kinase", and leads to a 713Glu-->Lys substitution in exon 8. As the analysis of the other markers within the DRD2 gene does not improve the strength of the association, our data are in favor of a specific role of the 3' chromosomic region of the DRD2 gene in the vulnerability to schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14741327     DOI: 10.1016/s0920-9964(03)00220-2

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  35 in total

1.  Polymorphisms in the DBH and DRD2 gene regions and smoking behavior.

Authors:  Maria Teresa M V Freire; Francine Z C Marques; Mara H Hutz; Claiton H D Bau
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-07-21       Impact factor: 5.270

2.  CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy.

Authors:  Paulo Roberto Xavier Tomaz; Juliana Rocha Santos; Jaqueline Scholz Issa; Tânia Ogawa Abe; Patrícia Viviane Gaya; José Eduardo Krieger; Alexandre Costa Pereira; Paulo Caleb Júnior Lima Santos
Journal:  Eur J Clin Pharmacol       Date:  2015-07-08       Impact factor: 2.953

3.  Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations.

Authors:  Rudi Hwang; Takahiro Shinkai; Vincenzo De Luca; Daniel J Müller; Xingqun Ni; Fabio Macciardi; Steven Potkin; Jeffrey A Lieberman; Herbert Y Meltzer; James L Kennedy
Journal:  Psychopharmacology (Berl)       Date:  2005-10-15       Impact factor: 4.530

4.  Updated findings of the association and functional studies of DRD2/ANKK1 variants with addictions.

Authors:  Yunlong Ma; Wenji Yuan; Xianzhong Jiang; Wen-Yan Cui; Ming D Li
Journal:  Mol Neurobiol       Date:  2014-08-20       Impact factor: 5.590

5.  Genetic Polymorphisms in the Dopamine Receptor 2 Predict Acute Pain Severity After Motor Vehicle Collision.

Authors:  Yawar J Qadri; Andrey V Bortsov; Danielle C Orrey; Robert A Swor; David A Peak; Jeffrey S Jones; Niels K Rathlev; David C Lee; Robert M Domeier; Phyllis L Hendry; Samuel A Mclean
Journal:  Clin J Pain       Date:  2015-09       Impact factor: 3.442

6.  D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis.

Authors:  Jian-Ping Zhang; Todd Lencz; Anil K Malhotra
Journal:  Am J Psychiatry       Date:  2010-03-01       Impact factor: 18.112

7.  Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios.

Authors:  M Daniele Fallin; Virginia K Lasseter; Dimitrios Avramopoulos; Kristin K Nicodemus; Paula S Wolyniec; John A McGrath; Gary Steel; Gerald Nestadt; Kung-Yee Liang; Richard L Huganir; David Valle; Ann E Pulver
Journal:  Am J Hum Genet       Date:  2005-10-28       Impact factor: 11.025

Review 8.  Dopamine genes and schizophrenia: case closed or evidence pending?

Authors:  Michael E Talkowski; Mikhil Bamne; Hader Mansour; Vishwajit L Nimgaonkar
Journal:  Schizophr Bull       Date:  2007-07-14       Impact factor: 9.306

9.  Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents.

Authors:  Chadi A Calarge; Vicki L Ellingrod; Laura Acion; Del D Miller; Jessica Moline; Michael J Tansey; Janet A Schlechte
Journal:  Pharmacogenet Genomics       Date:  2009-05       Impact factor: 2.089

10.  Molecular genetics of alcohol dependence and related endophenotypes.

Authors:  Yann L Strat; Nicolas Ramoz; Gunter Schumann; Philip Gorwood
Journal:  Curr Genomics       Date:  2008-11       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.